Lorlatinib
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Lorlatinib and local guidelines before prescribing.
Tyrosine kinase inhibitor
Mechanism
ALK tyrosine kinase inhibitor.
Uses
ALK-positive non-small-cell lung cancer.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Hypercholesterolaemia, cognitive and mood effects, oedema, weight gain.
Interactions
Strong CYP3A4 inducers contraindicated.
Contraindications and cautions
Strong CYP3A inducers
Monitoring
Lipids, ECG
Pregnancy and breastfeeding
Contraindicated
Renal and hepatic impairment
Caution in severe hepatic impairment
Overdose and reversal
Supportive
Special advice
Lipids and PR interval monitoring.
More from the textbook: uses, cautions and other points
- ALK: Alectinib or lorlatinib.
Respiratory: Lung Cancer - Alectinib / lorlatinib | Oral ALK inhibitors - ALK-positive NSCLC; good brain penetration. Lorlatinib: raised lipids, mood effects.
Respiratory: Lung Cancer
Where it is discussed in the book
- Respiratory: Lung Cancer (2 mentions)
- Integrated respiratory chapter (2 mentions)